
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/430988/publications.pdf Version: 2024-02-01



IDENE VANNI

#	Article	IF	CITATIONS
1	Relationship between the miRNA Profiles and Oncogene Mutations in Non-Smoker Lung Cancer. Relevance for Lung Cancer Personalized Screenings and Treatments. Journal of Personalized Medicine, 2021, 11, 182.	1.1	9
2	Germline ATM variants predispose to melanoma: a joint analysis across the GenoMEL and MelaNostrum consortia. Genetics in Medicine, 2021, 23, 2087-2095.	1.1	19
3	1482P Landscape of germline pathogenic variants beyond BRCA in pancreatic cancer patients. Annals of Oncology, 2021, 32, S1093.	0.6	0
4	Radiation-Related Deregulation of TUBB3 and BRCA1/2 and Risk of Secondary Lung Cancer in Women With Breast Cancer. Clinical Breast Cancer, 2020, 21, 218-230.e6.	1.1	2
5	Current State of Target Treatment in BRAF Mutated Melanoma. Frontiers in Molecular Biosciences, 2020, 7, 154.	1.6	82
6	Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications. Frontiers in Molecular Biosciences, 2020, 7, 172.	1.6	25
7	Quality assessment of a clinical next-generation sequencing melanoma panel within the Italian Melanoma Intergroup (IMI). Diagnostic Pathology, 2020, 15, 143.	0.9	0
8	1277P An exosomal miRNA signature as predictor of benefit from immune checkpoint inhibitors in non-small cell lung cancer. Annals of Oncology, 2020, 31, S825-S826.	0.6	2
9	Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer. Frontiers in Immunology, 2020, 11, 125.	2.2	53
10	The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape. Frontiers in Molecular Biosciences, 2020, 7, 113.	1.6	52
11	Insights into Genetic Susceptibility to Melanoma by Gene Panel Testing: Potential Pathogenic Variants in ACD, ATM, BAP1, and POT1. Cancers, 2020, 12, 1007.	1.7	19
12	Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab. Journal of Clinical Medicine, 2019, 8, 1566.	1.0	26
13	Coping with formalin banning in pathology: under vacuum long-term tissue storage with no added formalin. Histochemistry and Cell Biology, 2019, 151, 501-511.	0.8	7
14	Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients. Molecular Medicine, 2019, 25, 15.	1.9	22
15	The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients. Journal of Translational Medicine, 2019, 17, 74.	1.8	103
16	Integrated Somatic and Germline Whole-Exome Sequencing Analysis in Women with Lung Cancer after a Previous Breast Cancer. Cancers, 2019, 11, 441.	1.7	3
17	Twenty years of molecular analyses in amyotrophic lateral sclerosis: genetic landscape of Italian patients. Neurobiology of Aging, 2018, 66, 179.e5-179.e16.	1.5	16
18	P2.04-02 Predictive Value of Circulating Tumor Cells and Circulating Free DNA in NSCLC Patients Treated with Nivolumab. Journal of Thoracic Oncology, 2018, 13, S730-S731.	0.5	0

#	Article	IF	CITATIONS
19	P2.03-28 Whole Exome Sequencing to Discover Lung Tumor Predisposition in Women with Previous Breast Cancer. Journal of Thoracic Oncology, 2018, 13, S726-S727.	0.5	0
20	Lung cancer predisposition in women with previous breast cancer identified by whole exome sequencing. Annals of Oncology, 2018, 29, viii674.	0.6	0
21	Activating Killer Immunoglobulin Receptors and HLA-C: a successful combination providing HIV-1 control. Scientific Reports, 2017, 7, 42470.	1.6	21
22	Circulating Tumor DNA Reflects Tumor Metabolism Rather Than Tumor Burden in Chemotherapy-Naive Patients with Advanced Non–Small Cell Lung Cancer: <sup>18</sup> F-FDG PET/CT Study. Journal of Nuclear Medicine, 2017, 58, 1764-1769.	2.8	44
23	Understanding the checkpoint blockade in lung cancer immunotherapy. Drug Discovery Today, 2017, 22, 1266-1273.	3.2	48
24	P2.01-067 The Relevance of CEA and CYFRA21-1 as Predictive Factors in Nivolumab Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients. Journal of Thoracic Oncology, 2017, 12, S827-S828.	0.5	3
25	Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer. Expert Opinion on Investigational Drugs, 2017, 26, 551-561.	1.9	5
26	Exosomes: a new horizon in lung cancer. Drug Discovery Today, 2017, 22, 927-936.	3.2	90
27	New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer. Expert Opinion on Pharmacotherapy, 2017, 18, 19-33.	0.9	6
28	P1.07-023 The Correlation Between B7-H4 Expression and Survival of Non-Small Cell Lung Cancer Patients Treated with Nivolumab. Journal of Thoracic Oncology, 2017, 12, S2004-S2005.	0.5	0
29	Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy. International Journal of Molecular Sciences, 2017, 18, 1035.	1.8	39
30	Reply to the Letter to the Editor by C. Nicolazzo et al.: "Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy― International Journal of Molecular Sciences, 2017, 18, 1309.	1.8	1
31	Downregulation of miR-99a/let-7c/miR-125b miRNA cluster predicts clinical outcome in patients with unresected malignant pleural mesothelioma. Oncotarget, 2017, 8, 68627-68640.	0.8	27
32	Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma. MicroRNA (Shariqah, United Arab Emirates), 2016, 5, 12-18.	0.6	15
33	Whole-genome sequencing as standard practice for the analysis of clonality in outbreaks of meticillin-resistant Staphylococcus aureus in a paediatric setting. Journal of Hospital Infection, 2016, 93, 375-381.	1.4	22
34	Vinflunine for the treatment of non-small cell lung cancer. Expert Opinion on Investigational Drugs, 2016, 25, 1447-1455.	1.9	3
35	Performance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffin-embedded lung adenocarcinoma samples. BMC Cancer, 2016, 16, 692.	1.1	27
36	Whole exome sequencing of independent lung adenocarcinoma, lung squamous cell carcinoma, and malignant peritoneal mesothelioma. Medicine (United States), 2016, 95, e5447.	0.4	12

#	Article	IF	CITATIONS
37	Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma. Journal of Thoracic Oncology, 2015, 10, e50-e52.	0.5	11
38	3123 Correlation between circulating tumor biomarkers and positronemission tomography in advanced non-small cell lung cancer. European Journal of Cancer, 2015, 51, S644.	1.3	1
39	Clinical applications of a next-generation sequencing panel in non-small cell lung cancer. Annals of Oncology, 2015, 26, vi87.	0.6	0
40	Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in <scp>NSCLC</scp> cell lines poorly responsive to reversible <scp>EGFR</scp> tyrosine kinase inhibitors. International Journal of Cancer, 2015, 137, 2947-2958.	2.3	11
41	Next Generation Sequencing in Non-Small Cell Lung Cancer: New Avenues Toward the Personalized Medicine. Current Drug Targets, 2015, 16, 47-59.	1.0	38
42	Next-Generation Sequencing Workflow for NSCLC Critical Samples Using a Targeted Sequencing Approach by Ion Torrent PGMâ,,¢ Platform. International Journal of Molecular Sciences, 2015, 16, 28765-28782.	1.8	35
43	Afatinib for the treatment of non-small cell lung cancer. Expert Opinion on Orphan Drugs, 2015, 3, 1357-1364.	0.5	1
44	HLA-B and HLA-C Supratyping by Pyrosequencing®. Methods in Molecular Biology, 2015, 1315, 133-151.	0.4	1
45	Belagenpumatucel-L for the treatment of non-small cell lung cancer. Expert Opinion on Biological Therapy, 2015, 15, 1371-1379.	1.4	12
46	An improved method for HLA-B and -C supratyping. Journal of Immunological Methods, 2015, 426, 29-34.	0.6	2
47	MicroRNA prognostic signature in malignant pleural mesothelioma Journal of Clinical Oncology, 2015, 33, 7562-7562.	0.8	1
48	The role of circulating free DNA (cfDNA) and circulating tumor cells (CTC) in advanced non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy (CHT) Journal of Clinical Oncology, 2015, 33, e19090-e19090.	0.8	0
49	Abstract 4008: MiRNA expression profiling reveals a prognostic signature in malignant pleural mesothelioma. , 2015, , .		0
50	Abstract 2521: In vitro and in vivo antitumor efficacy of sequentially combined vinorelbine and gefitinib in non-small cell lung cancer. , 2015, , .		0
51	Efficacy of motesanib diphosphate in non-small-cell lung cancer. Expert Opinion on Pharmacotherapy, 2014, 15, 1771-1780.	0.9	0
52	Clinical Applications of Circulating Tumor Cells in Lung Cancer Patients by CellSearch System. Frontiers in Oncology, 2014, 4, 242.	1.3	63
53	Oral vinorelbine in the treatment of non-small-cell lung cancer. Expert Opinion on Pharmacotherapy, 2014, 15, 1585-1599.	0.9	22
54	Spontaneous control of HIV-1 viremia in a subject with protective HLA-B plus HLA-C alleles and HLA-C associated single nucleotide polymorphisms. Journal of Translational Medicine, 2014, 12, 335.	1.8	13

#	Article	IF	CITATIONS
55	A Sensible Technique to Detect Mollicutes Impurities in Human Cells Cultured in GMP Condition. Methods in Molecular Biology, 2014, 1160, 107-114.	0.4	о
56	Analysis of NADP+-dependent isocitrate dehydrogenase-1/2 gene mutations in pediatric brain tumors: report of a secondary anaplastic astrocytoma carrying the IDH1 mutation. Journal of Neuro-Oncology, 2012, 109, 477-484.	1.4	11
57	Development and validation of a multiplex quantitative polymerase chain reaction assay for the detection of Mollicutes impurities in human cells, cultured under good manufacturing practice conditions, and following European Pharmacopoeia requirements and the International Conference on Harmonization guidelines. Cytotherapy, 2012, 14, 752-766.	0.3	3
58	Detection of ganciclovir resistance mutations by pyrosequencing in HCMV-infected pediatric patients. Journal of Clinical Virology, 2012, 54, 48-55.	1.6	14
59	Killer Immunoglobulin-Like Receptors and Their Ligands. , 2012, , .		1
60	Molecular characterization of hospital-acquired methicillin-resistant Staphylococcus aureus strains in pediatric outbreaks using variable tandem repeat analysis with spa and ClfB typing. Diagnostic Microbiology and Infectious Disease, 2011, 69, 213-217.	0.8	12
61	Human leukocyte antigen–B (-Bw6/-Bw4 I80, T80) and human leukocyte antigen–C (-C1/-C2) subgrouping using pyrosequence analysis. Human Immunology, 2011, 72, 859-868.	1.2	10
62	Troubleshooting fineâ€ŧuning procedures for qPCR system design. Journal of Clinical Laboratory Analysis, 2011, 25, 389-394.	0.9	11